Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | SQLE | Q14534 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119326 | 1.00 | KMT2A (0.48) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL621377 | 1.00 | KMT2A (0.48) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL3885097 | 0.85 | KMT2A (0.45) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL19183172 | 0.84 | KMT2A (0.41) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5604645 | 0.83 | FNTA (0.58) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5604622 | 0.83 | FNTA (0.58) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL14867333 | 0.83 | KMT2A (0.47) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL15129571 | 0.83 | KMT2A (0.47) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL14867372 | 0.83 | KMT2A (0.47) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL5604249 | 0.83 | FNTA (0.58) | KMT2AALOX15MEN1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | GIVAUDAN SA (CH) | 2026-03-31 | — | — | US | claimed |
| US-12559703-B2 | Fragrance composition | GIVAUDAN SA (CH) | 2026-02-24 | — | — | US | claimed |
| EP-4695016-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2026-02-18 | — | — | EP | claimed |
| EP-4519404-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | Firmenich SA (CH) | 2025-03-12 | — | — | EP | claimed |
| CN-119403908-A | Method for enhancing psychological performance and composition for use in the method | 弗门尼舍有限公司 | 2025-02-07 | — | — | CN | claimed |
| WO-2024213507-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2024-10-17 | — | — | WO | claimed |
| EP-4446001-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2024-10-16 | — | — | EP | claimed |
| US-20240173230-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2024-05-30 | — | — | US | claimed |
| EP-4319715-A1 | FRAGRANCE COMPOSITION | Givaudan SA (CH) | 2024-02-14 | — | — | EP | claimed |
| WO-2023247604-A1 | METHODS FOR ENHANCING MENTAL PERFORMANCE AND COMPOSITIONS FOR USE THEREIN | FIRMENICH SA (CH) | 2023-12-28 | — | — | WO | claimed |
| US-20230084046-A1 | CONSUMER PRODUCT COMPRISING A PLURALITY OF MICROCAPSULES DEFINED BY THE MEAN TOTAL SURFACE AREA | GIVAUDAN SA (CH) | 2023-03-16 | — | — | US | claimed |
| EP-4146778-A1 | FRAGRANCE COMPOSITION | Givaudan SA (CH) | 2023-03-15 | — | — | EP | claimed |
| EP-4139041-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2023-03-01 | — | — | EP | claimed |
| CN-115666494-A | Encapsulated compositions comprising core-shell microcapsules and methods of making the same | 奇华顿股份有限公司 | 2023-01-31 | — | — | CN | claimed |
| EP-4120991-A1 | CONSUMER PRODUCT COMPRISING A PLURALITY OF MICROCAPSULES DEFINED BY THE MEAN TOTAL SURFACE AREA | Givaudan SA (CH) | 2023-01-25 | — | — | EP | claimed |
| WO-2022214636-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2022-10-13 | — | — | WO | claimed |
| US-11364184-B2 | Perfume compositions | GIVAUDAN SA (CH) | 2022-06-21 | — | — | US | claimed |
| WO-2021224201-A1 | FRAGRANCE COMPOSITION | GIVAUDAN SA (CH) | 2021-11-11 | — | — | WO | claimed |
| WO-2021213930-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2021-10-28 | — | — | WO | claimed |
| WO-2021185736-A1 | CONSUMER PRODUCT COMPRISING A PLURALITY OF MICROCAPSULES DEFINED BY THE MEAN TOTAL SURFACE AREA | GIVAUDAN SA (CH) | 2021-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589377-B2 | Encapsulated composition comprising core-shell microcapsules and process for its preparation | CUTA, EXOC1, EXOSC10 | KMT2A 4336/4885ALOX15 2323/4885MEN1 1693/4885 |
| US-12559703-B2 | Fragrance composition | DHCR24, OPRD1, OR10J3 | KMT2A 2244/4885ALOX15 40/4885MEN1 3398/4885 |
| US-20240173230-A1 | FRAGRANCE COMPOSITION | FABP2, FABP5, FAAH2 | KMT2A 1473/4885ALOX15 14/4885MEN1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.